Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY antimicrobial surveillance program, 2000

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 4, 2002, Pages 1032-1037

  Pfaller, Michael A ^a   Messer, S A ^a   Hollis, R J ^a   Jones, R N ^a   Steele Moore, L ^a   Dipersio, J R ^a   Overturf, G D ^a   Pfaller, M A ^a   Kehl, S ^a   Hardy, D ^a   Swanzy, S ^a   Fritsche, T ^a   Reisner, B ^a   Snyder, J ^a   Hazen, K ^a   Caroll, K ^a   Chapin, K ^a   Sharp, S ^a   Jenkins, S ^a   Rennie, R ^a   Toye, B ^a   more..

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; DRUG SURVEILLANCE PROGRAM; FUNGUS ISOLATION; FUSARIUM; MUCOR; NONHUMAN; PENICILLIUM; PRIORITY JOURNAL; RHIZOPUS;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CANADA; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; PYRIMIDINES; QUALITY CONTROL; THIAZOLES; TRIAZOLES; UNITED STATES;

EID: 0036205764     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.4.1032-1037.2002     Document Type: Article

References (39)

1. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates from the United States: 1992 to 1994 and 1996 to 1998
2. In vitro and in vivo activities of SCH 56592 (Posaconazole) a new triazole antifungal agent, against Aspergillus and Candida
3. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients
4. Burden of aspergillosis-related hospitalizations in the United States
5. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome
6. In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY antimicrobial surveillance program in North America and Latin America
7. Introduction to antifungal drugs
8. Comparison of in vitro activities of the new triazole SCH 56592 and the echinocandins MK-0991 (L-743, 872) and LY 303366 against opportunistic filamentous and dimorphic fungi and yeasts
9. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi
10. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation
11. Trends in the post-mortem epidemiology of invasive fungal infections at a university hospital
12. Potential new antifungal agents
13. Uncommon opportunistic fungi: New nosocomial threats
14. Emergence of cryptococcal disease: Epidemiologic perspectives 100 years after its discovery
15. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance
16. Critical assessment of issues in the diagnosis of invasive aspergillosis
17. Aspergillosis case-fatality rate: Systematic review of the literature
18. Antifungal activity of a new triazole, voriconazole (UK-109, 496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi
19. In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi
20. Comparison of voriconazole (UK-109, 496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs
21. In vitro evaluation of voriconazole against some clinically important fungi
22. Activity of voriconazole (UK-109, 496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis
23. Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys
24. In vitro activity of SCH 56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp
25. Efficacy of SCH 56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus
26. The new fungal opportunists are coming
27. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: Correlation with galactomannan antigenemia
28. The epidemiology of invasive mycoses - Narrowing the gap
29. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY program
30. International surveillance of bloodstream infections dues to Candida species in the European SENTRY program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents
31. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998
32. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibility to fluconazole, ravuconazole, and voriconazole among isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program
33. In vitro studies of activity of voriconazole (UK-109,4 96), a new triazole antifungal agent, against emerging and less common mold pathogens
34. The epidemiological features of invasive mycolic infections in the San Francisco Bay area, 1992-1993: Results of a population-based laboratory active surveillance
35. Current and emerging azole antifungal agents
36. Liposomal amphotericin B (AmBisome) for fungal infectons in immunocompromised adults and children
37. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients
38. Clinical surveillance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis